Cantor Fitzgerald Forecasts Biohaven FY2025 Earnings

Biohaven Ltd. (NYSE:BHVN - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Biohaven in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan forecasts that the company will post earnings of ($6.05) per share for the year. Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Biohaven's current full-year earnings is ($8.85) per share.

Several other equities research analysts also recently commented on the company. HC Wainwright restated a "buy" rating and set a $59.00 price objective on shares of Biohaven in a report on Tuesday, December 17th. TD Cowen upped their price objective on Biohaven from $55.00 to $75.00 and gave the company a "buy" rating in a research note on Wednesday, November 13th. Bank of America boosted their price target on shares of Biohaven from $52.00 to $62.00 and gave the company a "buy" rating in a research report on Tuesday, September 24th. Sanford C. Bernstein boosted their target price on Biohaven from $55.00 to $66.00 and gave the stock an "outperform" rating in a research report on Tuesday, September 24th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $61.00 price objective (up from $58.00) on shares of Biohaven in a report on Wednesday, December 4th. Thirteen investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Biohaven has an average rating of "Buy" and a consensus target price of $63.00.

Biohaven Stock Performance

Shares of NYSE BHVN traded up $1.53 during midday trading on Wednesday, reaching $40.56. The stock had a trading volume of 896,803 shares, compared to its average volume of 1,071,379. The firm has a market cap of $4.10 billion, a price-to-earnings ratio of -4.34 and a beta of 1.29. Biohaven has a twelve month low of $26.80 and a twelve month high of $62.21. The company's 50 day moving average price is $40.80 and its 200 day moving average price is $42.43.

Biohaven (NYSE:BHVN - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.70) EPS for the quarter, missing analysts' consensus estimates of ($1.67) by ($0.03).

Insider Buying and Selling

In other Biohaven news, Director John W. Childs bought 29,000 shares of the company's stock in a transaction dated Monday, December 30th. The stock was acquired at an average price of $35.94 per share, with a total value of $1,042,260.00. Following the completion of the acquisition, the director now directly owns 2,368,741 shares of the company's stock, valued at $85,132,551.54. This represents a 1.24 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 16.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Biohaven

Large investors have recently modified their holdings of the business. Hsbc Holdings PLC raised its position in shares of Biohaven by 6.1% during the 2nd quarter. Hsbc Holdings PLC now owns 8,291 shares of the company's stock worth $286,000 after acquiring an additional 480 shares in the last quarter. Public Employees Retirement Association of Colorado lifted its stake in Biohaven by 114.5% in the second quarter. Public Employees Retirement Association of Colorado now owns 7,796 shares of the company's stock valued at $271,000 after buying an additional 4,162 shares during the last quarter. Profund Advisors LLC increased its holdings in shares of Biohaven by 42.4% in the 2nd quarter. Profund Advisors LLC now owns 36,239 shares of the company's stock valued at $1,258,000 after acquiring an additional 10,786 shares during the period. Magnetar Financial LLC acquired a new stake in Biohaven during the 2nd quarter worth $2,061,000. Finally, Farallon Capital Management LLC raised its holdings in shares of Biohaven by 181.4% in the second quarter. Farallon Capital Management LLC now owns 2,248,000 shares of the company's stock valued at $78,028,000 after buying an additional 1,449,000 shares during the last quarter. Institutional investors and hedge funds own 88.78% of the company's stock.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.